Drug Profile

AEG 33783

Alternative Names: AEG33783

Latest Information Update: 15 Mar 2007

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aegera Therapeutics
Class Antineoplastics; Neuroprotectants
Mechanism of Action HSP70 heat shock protein stimulants; JNK mitogen-activated protein kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Cancer; Diabetic neuropathies; Peripheral nervous system diseases

Most Recent Events

15 Mar 2007 Discontinued - Phase-I for Peripheral nervous system diseases in Canada (IV)
15 Mar 2007 Discontinued - Preclinical for Cancer in Canada (IV)
15 Mar 2007 Discontinued - Preclinical for Diabetic neuropathies in Canada (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com